Annexon outlines 2024 clinical milestones: Phase 3 GBS data H1 2024, GA trial start mid-2024

Annexon, Inc.

Phase 3 pivotal data for ANX005 in Guillain-Barré syndrome on track for first half of 2024; potential first approved treatment in U.S.
Global pivotal program for ANX007 in geographic atrophy (ARCHER II) to initiate mid-2024 with vision preservation as primary endpoint
Proof-of-concept study for oral C1s inhibitor ANX1502 in cold agglutinin disease to start first half of 2024
Completed $125 million financing extends operating runway into second quarter 2026
ANX007 received PRIME designation in EU; to launch head-to-head ARROW trial vs. SYFOVRE in late 2024

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.